Astellas Pharma Inc. announced the FDA accepted the revised supplemental New Drug Application (sNDA) for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary… read more.
Researchers from RMIT University have developed a wearable wound monitoring device with integrated sensors that could reduce infection risks by minimising the need for frequent physical contact. Standard… read more.
To diagnose either type 2 diabetes or pre-diabetes, clinicians typically rely on a lab value known as HbA1c. This test captures a person’s average blood glucose levels over… read more.
The EMA revealed that Pfizer had withdrawn its application submitted on December 20, 2024, for variation to the marketing authorisation for Ngenla to treat adults with growth hormone… read more.
Optical coherence tomography (OCT), a tool routinely used to diagnose and plan treatment for eye diseases, has now been modified to collect images of the inner ear. A… read more.
A new study from researchers at the Indiana University Paul H. O’Neill School of Public and Environmental Affairs and the University of Notre Dame shows that per- and… read more.
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer (NSCLC) at… read more.
Nearly half of drug-caused deaths by healthcare workers involved drugs that were obtained from their place of work, new research finds. The study, published today in Addiction by… read more.
Amgen announced that the FDA has approved Lumakras (sotorasib) in combination with Vectibix (panitumumab) for the treatment of adult patients with KRAS G12C-mutated metastatic colorectal cancer (mCRC), as… read more.
Americans who drink heavily are more than twice as likely to develop significant liver disease compared to 20 years ago, according to a new Keck Medicine of USC… read more.
Urgent care visits commonly result in inappropriate prescriptions of antibiotics, glucocorticoids or opioids, according to a letter in the Annals of Internal Medicine. Michigan Medicine researchers examined commercial… read more.
The first patient has been dosed in the DESTINY-Gastric05 phase IIII trial evaluating Enhertu (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Merck’s anti-PD-1… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
